Z-138: a new mature B-cell acute lymphoblastic leukemia cell line from a patient with transformed chronic lymphocytic leukemia.
We describe a new mature B-cell acute lymphoblastic leukemia (ALL) cell line designated Z-138 that was derived from a patient with chronic lymphocytic leukemia (CLL) whose disease underwent transformation to a rare, aggressive form of mature B-cell ALL. This cell line has an L3 morphology, ultrastructural characteristics of lymphoblasts, B-lineage surface markers and an immunoglobulin heavy-chain gene rearrangement identical to the rearrangement observed in the patient's blasts from whom the cell line was derived. Z-138 cells produce granulocyte-macrophage colony-stimulating factor (GM-CSF) and high levels of granulocyte-CSF (G-CSF), but they do not exhibit a proliferative response to either cytokine. Both the patient's lymphoblasts and Z-138 cells exhibited cytogenetic abnormalities including t(8;14), t(14;18) and a chromosome 11 abnormality similar to the t(11;14) of the parental cells, resulting in marked overexpression of cyclin D1 (BCL-1 (PRAD1)) mRNA in Z-138 cells. Since these karyotypic anomalies have been associated with low grade (t(14;18)), intermediate grade (t(11;14)) and high grade (t(8;14)) lymphomas, their development may be involved in the unusual aggressive transformation of this patient's CLL.
Department of Bioimmunotherapy, The University of Texas, M.D. Anderson Cancer Center, Houston 77030, USA.
Z
Z
Estrov
M
M
Talpaz
S
S
Ku
D
D
Harris
Q
Q
Van
M
M
Beran
C
C
Hirsch-Ginsberg
Y
Y
Huh
G
G
Yee
R
R
Kurzrock
D000368:Aged; D015139:Blotting, Southern; D001854:Bone Marrow Cells / Q000473:pathology; D002051:Burkitt Lymphoma / Q000209:etiology* / Q000276:immunology / Q000473:pathology*; D002471:Cell Transformation, Neoplastic / Q000473:pathology*; D002472:Cell Transformation, Viral; D002869:Chromosome Aberrations / Q000235:genetics*; D002899:Chromosomes, Human, Pair 9 / Q000235:genetics*; D002999:Clone Cells / Q000737:chemistry; D004247:DNA / Q000032:analysis; D016044:Fusion Proteins, bcr-abl / Q000096:biosynthesis; D015326:Gene Rearrangement, B-Lymphocyte, Heavy Chain / Q000235:genetics; D016179:Granulocyte Colony-Stimulating Factor / Q000096:biosynthesis / Q000494:pharmacology; D016178:Granulocyte-Macrophage Colony-Stimulating Factor / Q000096:biosynthesis / Q000494:pharmacology; D004854:Herpesvirus 4, Human / Q000302:isolation & purification; D006801:Humans; D007144:Immunoglobulin J-Chains / Q000235:genetics; D016130:Immunophenotyping; D007375:Interleukin-1 / Q000096:biosynthesis; D015850:Interleukin-6 / Q000096:biosynthesis; D007621:Karyotyping; D015451:Leukemia, Lymphocytic, Chronic, B-Cell / Q000473:pathology*; D008213:Lymphocyte Activation / Q000187:drug effects; D008297:Male; D008854:Microscopy, Electron; D012313:RNA / Q000032:analysis; D016212:Transforming Growth Factor beta / Q000096:biosynthesis; D014407:Tumor Cells, Cultured / Q000166:cytology* / Q000502:physiology / Q000821:virology; D014409:Tumor Necrosis Factor-alpha / Q000096:biosynthesis
D007144:Immunoglobulin J-Chains; D007375:Interleukin-1; D015850:Interleukin-6; D016212:Transforming Growth Factor beta; D014409:Tumor Necrosis Factor-alpha; D016179:Granulocyte Colony-Stimulating Factor; D012313:RNA; D016178:Granulocyte-Macrophage Colony-Stimulating Factor; D004247:DNA; D016044:Fusion Proteins, bcr-abl